[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL2076494T3 - Podstawione przez piperydynę lub piperazynę pochodne kwasu tetrahydronaftaleno-1-karboksylowego hamujące MTP - Google Patents

Podstawione przez piperydynę lub piperazynę pochodne kwasu tetrahydronaftaleno-1-karboksylowego hamujące MTP

Info

Publication number
PL2076494T3
PL2076494T3 PL07821650T PL07821650T PL2076494T3 PL 2076494 T3 PL2076494 T3 PL 2076494T3 PL 07821650 T PL07821650 T PL 07821650T PL 07821650 T PL07821650 T PL 07821650T PL 2076494 T3 PL2076494 T3 PL 2076494T3
Authority
PL
Poland
Prior art keywords
piperidine
naphthalene
carboxylic acid
inhibiting compounds
substituted tetrahydro
Prior art date
Application number
PL07821650T
Other languages
English (en)
Inventor
Lieven Meerpoel
Joannes Theodorus Maria Linders
Libuse Jaroskova
Marcel Viellevoye
Leo Jacobus Jozef Backx
Didier Jean-Claude Berthelot
Guuske Frederike Busscher
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PL2076494T3 publication Critical patent/PL2076494T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL07821650T 2006-10-24 2007-10-22 Podstawione przez piperydynę lub piperazynę pochodne kwasu tetrahydronaftaleno-1-karboksylowego hamujące MTP PL2076494T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06122817 2006-10-24
PCT/EP2007/061286 WO2008049806A1 (en) 2006-10-24 2007-10-22 Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid mtp inhibiting compounds
EP07821650A EP2076494B1 (en) 2006-10-24 2007-10-22 Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid mtp inhibiting compounds

Publications (1)

Publication Number Publication Date
PL2076494T3 true PL2076494T3 (pl) 2011-01-31

Family

ID=37885794

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07821650T PL2076494T3 (pl) 2006-10-24 2007-10-22 Podstawione przez piperydynę lub piperazynę pochodne kwasu tetrahydronaftaleno-1-karboksylowego hamujące MTP

Country Status (28)

Country Link
US (1) US8114880B2 (pl)
EP (1) EP2076494B1 (pl)
JP (1) JP5506085B2 (pl)
KR (1) KR101415536B1 (pl)
CN (1) CN101528695B (pl)
AR (1) AR063517A1 (pl)
AT (1) ATE475648T1 (pl)
AU (1) AU2007310925B2 (pl)
BR (1) BRPI0717357A2 (pl)
CA (1) CA2664141C (pl)
CL (1) CL2007003042A1 (pl)
CY (1) CY1111010T1 (pl)
DE (1) DE602007008124D1 (pl)
DK (1) DK2076494T3 (pl)
EA (1) EA016311B1 (pl)
HK (1) HK1136823A1 (pl)
IL (1) IL198332A (pl)
JO (1) JO2653B1 (pl)
MX (1) MX2009004386A (pl)
NO (1) NO20092005L (pl)
NZ (1) NZ575615A (pl)
PL (1) PL2076494T3 (pl)
PT (1) PT2076494E (pl)
SI (1) SI2076494T1 (pl)
TW (1) TWI396688B (pl)
UA (1) UA99109C2 (pl)
WO (1) WO2008049806A1 (pl)
ZA (1) ZA200902822B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
ATE469122T1 (de) 2006-10-24 2010-06-15 Janssen Pharmaceutica Nv Mtp-inhibierende tetrahydronaphthalin-1- carbonsäurederivate
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
SI2629776T1 (sl) 2010-10-18 2017-12-29 Cerenis Therapeutics Holding Sa Spojine, sestavki in postopki, uporabni za mobilizacijo holesterola
MY191366A (en) 2013-03-13 2022-06-20 Forma Therapeutics Inc Novel compounds and compositions for inhibition of fasn
EP3484528B1 (en) 2016-07-18 2020-11-25 Janssen Pharmaceutica NV Tau pet imaging ligands
JP6960532B2 (ja) * 2018-05-15 2021-11-05 旭化成株式会社 アミノ酸アミノアルキルエステル又はその無機酸塩の製造方法
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
WO2024006701A1 (en) * 2022-06-28 2024-01-04 Stepan Company Method for making dialkyl amino acid ester sulfonates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
WO1996040640A1 (en) 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
BR9714364A (pt) 1996-11-27 2000-03-21 Pfizer Amidas inibidoras da secreção de apo b/mtp
GB9826412D0 (en) 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
DE19963235A1 (de) * 1999-12-27 2001-07-05 Boehringer Ingelheim Pharma Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
FR2816940A1 (fr) * 2000-11-23 2002-05-24 Lipha Derives de 4-(biphenylcarbonylamino)-piperidine, compositions les contenant et leur utilisation
ATE469122T1 (de) 2006-10-24 2010-06-15 Janssen Pharmaceutica Nv Mtp-inhibierende tetrahydronaphthalin-1- carbonsäurederivate

Also Published As

Publication number Publication date
AU2007310925A1 (en) 2008-05-02
JP2010507615A (ja) 2010-03-11
SI2076494T1 (sl) 2010-11-30
US8114880B2 (en) 2012-02-14
DK2076494T3 (da) 2010-11-08
CA2664141C (en) 2015-04-28
EA200970398A1 (ru) 2009-08-28
ATE475648T1 (de) 2010-08-15
NZ575615A (en) 2011-01-28
MX2009004386A (es) 2009-05-08
CA2664141A1 (en) 2008-05-02
PT2076494E (pt) 2010-10-18
US20090325980A1 (en) 2009-12-31
NO20092005L (no) 2009-06-04
CY1111010T1 (el) 2015-06-11
KR101415536B1 (ko) 2014-07-16
JP5506085B2 (ja) 2014-05-28
AR063517A1 (es) 2009-01-28
IL198332A0 (en) 2010-02-17
IL198332A (en) 2012-08-30
CN101528695B (zh) 2013-07-17
AU2007310925B2 (en) 2012-07-26
HK1136823A1 (en) 2010-07-09
EP2076494B1 (en) 2010-07-28
TW200833680A (en) 2008-08-16
TWI396688B (zh) 2013-05-21
BRPI0717357A2 (pt) 2013-10-22
UA99109C2 (ru) 2012-07-25
CN101528695A (zh) 2009-09-09
DE602007008124D1 (de) 2010-09-09
CL2007003042A1 (es) 2008-05-02
KR20090075832A (ko) 2009-07-09
WO2008049806A1 (en) 2008-05-02
ZA200902822B (en) 2010-07-28
JO2653B1 (en) 2012-06-17
EP2076494A1 (en) 2009-07-08
EA016311B1 (ru) 2012-04-30

Similar Documents

Publication Publication Date Title
ZA200902822B (en) Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid MTP inhibiting compounds
HUS1900033I1 (hu) Szubsztituált enaminokarbonil vegyületek
PL2079727T3 (pl) Inhibitory kinazy
EP2085383A4 (en) Piperidin derivatives or salts thereof
ZA200804393B (en) Heteroaryl substituted piperidine derivatives as L-CPT1 inhibitors
EP2120573A4 (en) DERIVATIVES OF PIPERIDINE
IL210990A0 (en) Piperidine derivatives as jak3 inhibitors
HRP20130004T8 (en) 4-substituted phenoxyphenylacetic acid derivatives
IL194356A0 (en) Novel cyclobutyl compounds as kinase inhibitors
IL195158A0 (en) Novel heterocyclic compounds
EP2120578A4 (en) KINASE INHIBITOR COMPOUNDS
ZA200902002B (en) Piperidine derivatives
EP2166857A4 (en) KINASE INHIBITOR COMPOUNDS
ZA200900625B (en) Substituted 1-(azolin-2-yl)-amino-2-aryl-1-hetaryl-ethane compounds
IL188371A0 (en) Novel piperidine derivatives
EP2283000A4 (en) 3- OR 4-SUBSTITUTED PIPERIDINE COMPOUNDS
ZA201000917B (en) Piperidine derivative
ZA200904327B (en) Substituted piperidines containing a heteroarylamide or heteroarylphenyl moiety
ZA200901570B (en) Substituted azolin-2-YL-amino compounds
ZA200709230B (en) Novel piperidine derivatives
ZA200809385B (en) Novel heterocyclic compounds
EP1940411A4 (en) MACROHETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
GB0512943D0 (en) Indazole-1-acetic acid compounds
GB0619308D0 (en) Heterocyclic compounds
GB0624901D0 (en) Novel compounds E